Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Published:2020-04 Issue: Volume:129 Page:107-116
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Negrier Sylvie,Rioux-Leclercq Nathalie,Ferlay Céline,Gross-Goupil Marine,Gravis Gwenaëlle,Geoffrois Lionel,Chevreau Christine,Boyle Helen,Rolland Frederic,Blanc Ellen,Ravaud Alain,Dermeche Slimane,Flechon Aude,Albiges Laurence,Pérol David,Escudier Bernard

Funder

Centre Leon Berard

Pfizer

Ipsen

BMS

EUSA Pharma

Novartis

MSD

Roche

AstraZeneca

Sanofi

Astellas

Bristol-Myers Squibb

MSD AVENIR

Aveo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Characterizing the outcomes of metastatic papillary renal cell carcinoma;Connor;Cancer Med,2017

2. Comprehensive molecular characterization of papillary renal-cell carcinoma;Linehan;N Engl J Med,2016

3. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma;Ricketts;Cell Rep,2018

4. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array;Albiges;Clin Canc Res,2014

5. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances;American Society of Clinical Oncology Educational Book;2024-06

2. Papillary Renal Cell Carcinoma: Current Evidence and Future Directions;Kidney Cancer;2024-05-07

3. Novel molecular classification and prognosis of papillary renal cell carcinoma based on a large-scale CRISPR-Cas9 screening and machine learning;Heliyon;2024-01

4. Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma;Journal for ImmunoTherapy of Cancer;2023-11

5. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database;Cancer Medicine;2023-10-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3